Marshall Wace’s Structure Therapeutics GPCR Stock Holding History

Marshall Wace’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.33M	Sell	69,107 -99,477	-59%	-$6.81M	﹤0.01%	1516
2025 Q4	$11.7M	Buy	+168,584	New	+$6.88M	0.01%	815
2025 Q3	–	Sell	-176,060	Closed	-$3.65M	–	3071
2025 Q2	$3.65M	Buy	176,060 +145,434	+475%	+$3.2M	﹤0.01%	1299
2025 Q1	$530K	Sell	30,626 -552,581	-95%	-$13.5M	﹤0.01%	2057
2024 Q4	$15.8M	Buy	583,207 +450,531	+340%	+$16M	0.02%	619
2024 Q3	$5.82M	Buy	132,676 +56,742	+75%	+$2.19M	0.01%	938
2024 Q2	$2.98M	Buy	75,934 +40,693	+115%	+$1.67M	﹤0.01%	1199
2024 Q1	$1.51M	Sell	35,241 -70,529	-67%	-$2.97M	﹤0.01%	1490
2023 Q4	$4.31M	Sell	105,770 -1,748	-2%	-$100K	0.01%	960
2023 Q3	$5.42M	Buy	+107,518	New	+$3.46M	0.01%	844

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Marshall Wace's GPCR Position: Q1 2026 in Review

Marshall Wace reduced its Structure Therapeutics (GPCR) stake by 59% in Q1 2026, selling an estimated $6.81M and leaving 69,107 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1516.

Marshall Wace first reported a position in GPCR in Q3 2023 and has held it in 10 quarters since. The position peaked at $15.8M in Q4 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Marshall Wace held 69,107 shares of Structure Therapeutics worth $3.33M as of Q1 2026.
Marshall Wace sold 99,477 Structure Therapeutics shares in Q1 2026, an estimated $6.81M.
Structure Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1516 holding.
Marshall Wace first reported a position in Structure Therapeutics in Q3 2023 and has held it in 10 quarters since.
Marshall Wace's Structure Therapeutics position peaked at $15.8M in Q4 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.